PARP Inhibitors in Prostate Cancer

Area of Science:

• Oncology
• Genomics
• Pharmacology

Background:

• Metastatic prostate cancer (mPCa) frequently harbors actionable genomic alterations.
• Over 20% of mPCa patients exhibit somatic DNA repair gene defects (DRD), presenting a therapeutic vulnerability.

Purpose of the Study:

• To explore the therapeutic potential of poly (ADP-ribose) polymerase inhibitors (PARPi) in mPCa.
• To investigate the role of DNA repair gene defects (DRD) as predictive biomarkers for PARPi efficacy.

Main Methods:

• Review of clinical trial data for PARPi in mPCa patients with DRD.
• Analysis of genomic landscapes in mPCa to identify actionable mutations and DRD.
• Evaluation of combination strategies involving PARPi.

Main Results:

• PARPi demonstrated significant response rates, up to 88%, in mPCa patients with specific DRD (e.g., BRCA1/2, ATM).
• Olaparib received FDA "breakthrough designation" for treating this mPCa subset.

Conclusions:

• PARPi represent a promising therapeutic strategy for a subset of mPCa patients with DRD.
• Ongoing research focuses on optimizing PARPi use through combination therapies, biomarker development, and well-designed clinical trials.